Please login to the form below

Not currently logged in
Email:
Password:

hepatocellular carcinoma

This page shows the latest hepatocellular carcinoma news and features for those working in and with pharma, biotech and healthcare.

Transgene slumps as viral cancer therapy fails phase 3 trial

Transgene slumps as viral cancer therapy fails phase 3 trial

PHOCUS was testing whether a dose of Pexa-Vec given ahead of Nexavar could improve outcomes in hepatocellular carcinoma (HCC), the most common form of liver cancer, and had been due

Latest news

More from news
Approximately 1 fully matching, plus 47 partially matching documents found.

Latest Intelligence

  • Making Europe a leader in bioscience: boosting trust and opening minds Making Europe a leader in bioscience: boosting trust and opening minds

    This public-private research alliance is aimed at improving survival rates in hepatocellular carcinoma (the primary cancer of the liver).

  • Chinese biotech’s global ambitions Chinese biotech’s global ambitions

    Tislelizumab is in global phase III trials in a number of tumour types, including non-small cell lung cancer, hepatocellular carcinoma and oesophageal squamous cell carcinoma. ... It’s also in phase II trials in patients with previously treated

  • Deal Watch March 2016 Deal Watch March 2016

    Collaboration – discovery, development &commercialisation. $965. Exelixis/ Ipsen. Cabozantinib (Renal Cell Carcinoma, Hepatocellular Carcinoma, other indications) and Cometriq (medullary thyroid cancer).

  • Medius Deal Watch table for April 2015 Medius Deal Watch table for April 2015

    120. 4SC AG/Menarini. Licensing and development agreement. Resminostat (oral HDAC) for hepatocellular carcinoma.

  • Pharma deals in April 2015 Pharma deals in April 2015

    deacetylase (HDAC) inhibitor in all oncological indications, in particular hepatocellular carcinoma in Asia Pacific (excluding Japan).

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

PANDAS/PANS Awareness: A parent’s story
To help raise awareness of these often underdiagnosed diseases, Jon Hallows, Joint MD at Porterhouse shares his own experience as a parent of a son recently diagnosed with PANDAS...
Iskra Reic
Leading AstraZeneca’s return to growth in Europe
PME talks to Iskra Reic, the company’s head of Europe and Canada...
The era of digital wellbeing
Social media - friend or foe?...

Infographics